Add BrightSurf on Google Email

First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateJul 27, 2026

Biggs Institute at UT Health San Antonio to lead $2.5 million national, multi-site study on dementia with Lewy bodies

The Biggs Institute is leading a $2.5 million national, multi-site study to improve detection and diagnosis of dementia with Lewy bodies. The study will enroll 125 participants and evaluate multiple possible new tools and methods to accurately identify individuals who have accumulated abnormal alpha-synuclein in the brain.

Simple digital check-ins improve outcomes for cancer patients, AFT study finds

A new study found that simple weekly electronic symptom check-ins with care teams significantly improves the quality of life for individuals undergoing treatment for advanced cancer. The benefits were notable among patient groups that historically faced barriers to care, including Black patients and those with less formal education.

SourceAlliance for Clinical Trials in Oncology·JournalJCO Oncology Practice·TypeRandomized controlled/clinical trial·DateJul 13, 2026

HonorHealth Research Institute is among first in the nation to expand access to new drug that doubles survival of pancreatic cancer patients

The FDA has granted early access to clinical trials for the new medication, allowing HonorHealth Research Institute to offer it to patients with previously treated metastatic pancreatic cancer. The drug has shown significant advancement in targeted therapy for pancreatic cancer, offering a median overall survival of 13.2 months.

SourceHonorHealth Research Institute·TypeRandomized controlled/clinical trial·DateJul 7, 2026

Calgary man says clinical trial gave him hope when he had none

Researchers at the University of Calgary have developed a novel CAR T-cell therapy called GCAR1, showing strong preclinical and early clinical promise in treating sarcoma and other cancers. The therapy has been tested on two Canadian patients, with one patient experiencing significant prolongation of life expectancy by 18 months.

SourceUniversity of Calgary·TypeRandomized controlled/clinical trial·DateJul 2, 2026

AI support tool improved clinician decisions in real-world primary care trial

A large clinical trial found that an AI support tool improved the quality of clinical documentation and treatment planning, but did not significantly change short-term patient outcomes. The study involved over 9,600 patients in Kenya and used a randomized controlled design to test the effectiveness of the AI tool.

SourceUniversity of Birmingham·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 26, 2026

NATO battlefield surgery training and surgical simulations among the first courses at Semmelweis University’s new Innovation Center

Semmelweis University's new Anatomy & Innovation Center for Education and Research has hosted two NATO battlefield surgery courses, providing realistic environments for learning and practicing new procedures. The center aims to improve patient safety and quality of care through advanced technologies and hands-on training.

Seasoned federal administrator selected by HonorHealth Research Institute to help drive patients’ expanding clinical trial choices

Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.

SourceHonorHealth Research Institute·TypeRandomized controlled/clinical trial·DateJun 15, 2026

Internationally recognized oncology drug development leader and melanoma expert joins HonorHealth Research Institute

Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.

SourceHonorHealth Research Institute·TypeRandomized controlled/clinical trial·DateJun 4, 2026

Early birth safer for mother and baby in high blood pressure pregnancies

A new Cochrane review finds planned early birth for pregnant women with high blood pressure cuts maternal complications by nearly half and reduces the risk of stillbirth. The practice is found to be safe across both high- and low-income settings, without increasing the likelihood of caesarean section.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateMay 20, 2026

Reusable catheters a safe choice that could save NHS millions, study finds

A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.

SourceUniversity of Southampton·JournalInternational Journal of Nursing Studies·TypeMeta-analysis·DateMay 20, 2026

Chinese Neurosurgical Journal study finds most basilar trunk aneurysms treatable with minimally invasive techniques

A new study published in the Chinese Neurosurgical Journal found that most basilar trunk artery aneurysms can be treated effectively using endovascular techniques, resulting in encouraging long-term recovery rates. However, larger aneurysms pose higher treatment risks and are associated with complications and poorer outcomes.

SourceChinese Neurosurgical Journal·JournalChinese Neurosurgical Journal·TypeObservational study·DateMay 14, 2026

Screening modestly reduces prostate cancer deaths

Screening with a PSA blood test reduces prostate cancer deaths by approximately 2 for every 1,000 men screened. The review found that 500 men would need to be invited to screening to prevent one prostate cancer death.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateMay 14, 2026

Viagra could hold key to halting Peyronie’s disease

A new study published in The Journal of Sexual Medicine found that combining phosphodiesterase type 5 inhibitors with selective oestrogen receptor modulators may slow or stop disease progression when given early. This combination resulted in improved penile curvature and reduced pain during erections compared to standard care.

SourceAnglia Ruskin University·JournalThe Journal of Sexual Medicine·DateMay 14, 2026

Chinese Medical Journal article review highlights a growing global consensus on acute-on-chronic liver failure

Researchers agree on core elements of ACLF development, including chronic liver disease triggers, acute insult, and extrahepatic organ failure. A new three-stage mouse model supports testing of potential therapies, highlighting impaired liver regeneration as a key driver of disease progression.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 28, 2026

Re-conceptualizing Parkinson’s disease as a lifelong neurobiological trajectory: A framework for prevention

A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalNeuroprotection·TypeLiterature review·DateApr 28, 2026

New research from the COSMOS trial reveals more than 75% of older adults have used complementary therapies

A new study reveals that over 75% of older adults have used complementary health approaches, including mindfulness, yoga, tai chi, acupuncture, and more. The study highlights the need for healthcare providers to discuss the risks and benefits of these therapies with their patients.

SourceBrigham and Women's Hospital·JournalThe American Journal of Medicine·TypeData/statistical analysis·DateApr 24, 2026

Alliance study shows new promise against locally advanced lung cancer

A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...

SourceAlliance for Clinical Trials in Oncology·JournalLung Cancer·TypeExperimental study·DateApr 20, 2026

Exercise and cancer research: Ibuprofen is another option to ease chemo-brain

A new study suggests that a low dose of ibuprofen can help alleviate chemo-brain symptoms in cancer patients, but exercise remains the most beneficial intervention. Researchers randomized 86 patients to receive either exercise plus ibuprofen or other treatments and found that exercise significantly improved cognitive function.

SourceUniversity of Rochester Medical Center·JournalCancer·TypeRandomized controlled/clinical trial·DateApr 20, 2026